Nuper, JMYMUS Technology Co., Ltd. nuntiatum est Leuprorelin acetate, produci per eius subsidiary Hubei Jx bio-pharmaceutical Co., Ltd., feliciter Transierunt medicamento adnotatione inspectionem.
Original Original Original
Leuprorelin Acetate est injectable medicamento solebat tractare hormone, dependens morbos, cum Molecular formula c59h84n16o12 • XC2H4O2. Est gonadotropin, releasing hormone agonist (GNRHA), qui operatur per inhibentes in pituitam-gonadal ratio. Primitus co-developed ab abbvie et Takeda pharmaceutical, hoc medicamento est venales per diversas notam nomina in variis regionibus. In Civitatibus Foederatis Americae, quod vendidit in notam nomen Lupron vectum, dum in Sina, quod est venalicium sicut Yina lingua.
Patet processus et bene defined roles
Ex MMXIX ad MMXXII, in pharmaceutical investigationis et progressionem perficitur, sequitur ab Registration API in March MMXXIV, cum acceptatio notitiam receptum est. In Medicamento Registration inspectionem erat in August MMXXIV. Jymmed Technology Co., Ltd. erat responsible pro process development, analytica modum progressionem, innumeris studiis, structuram confirmatio, et ratio sanatio. Hubei jx bio-pharmaceutical Co., Ltd erat in praefectum processu sanationis productio, analytica ratio sanatio et stabilitatem studiis ad API.
Expanding foro et crescente demanda
Et ortu incidentiae de prostate cancer et vteri fibroids est driving augeri demanda leuprorelin ACETATE. Et North American Market currently dominatur Leuprorelin Acetate foro, cum crescente curis Sumptus et excelsum acceptatio novi technologiae esse primaria incrementum coegi. Eodem tempore Asian foro, praecipue Sinis, etiam showing fortis demanda leuprorelinin acetate. Ex eius efficaciam, global demanda huic medicamento est in ortum, cum in foro mole expectata ad pervenire USD 3,946.1 decies a MMXXXI, reflectendo a compositis annuis augmentum rate (Cagr in MMXXXI a compositis annuis (Cagr in MMXXI ad MMXXI.
De jymmed
Shenzhen jymmed technology Co., Ltd. (Hereñafter referred to as jmed) in statutum est in MMIX, specialiter in investigationis, progressionem, productio et venditionesque peptides et peptide actis products. Et unum investigationis centrum et tres major productionem bases, jymmed est unus de maxima effectrix chemica synthesized peptide apis in Sinis. In Company scriptor core R & D quadrigis quatenus super XX annos experientia in peptide industria et feliciter Transierunt FDA inspectionibus bis. Jymmed scriptor comprehensive et efficens peptide industrialization ratio praebet customers a plena range of muneris, comprehendo ad progressionem et productionem therapeutic peptides, VETERINARIUS peptides, antimicrobial peptides, et regulatory peptides, tum adnotatione et regulatory Support.
Pelagus res actiones
1.Gomestis et International Registration of Peptide Apis
2.veterinary et COLOR peptides
3.Custom peptides et Cro, CMO, OEM Services
4.pdc medicamina (peptide-radionuclide, peptide-parva molecule, peptide, dapibus, peptide-rna)
Praeterea ad Leuprorelin Acetate, jymmed est summitto adnotatione limatura cum FDA et Cde pro pluribus aliis API products, comprehendo in currently popularibus GLP-1ra genus pharmas ut semaglutide, Liraglutide et Tirzepatide. Future customers per jymmed scriptor products poterit ad directe referat ad Cde adnotatione numero vel DMF file numerus cum submittendo adnotatione applications ad FDA aut Cde. Hoc autem significantly reducere tempus requiritur ad parat application documenta, tum iudicium et tempus et sumptus of productum recensionem.
Contact Us
Shenzhen jymmed technology Co., Ltd.
Oratio:8th & 9th contignationibus, aedificationem I, Shenzhen biomedical innovation Industrial Park, No. XIV Jinhui Road, Kengzi subdristic, Pingshan regio, Shenzhen
Phone:LXXXVI 755-26612112
Website:http://www.jymedtech.com/
Post tempus: Aug-29-2024
